Christian Confavreux

Pathology and Forensic Medicine · 2000–2012

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Pathology and Forensic Medicine — 20 citations into it; #109 of 414 by trust here, #109 by citations

Whom Christian Confavreux trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Sandra Vukusic

Who trusts Christian Confavreux overall

1. Sandra Vukusic
2. Stephen L. Hauser
3. Hans Lassmann
4. Jorge R. Oksenberg
5. C. Lucchinetti

Papers from Christian Confavreux's perspective

Ordered by how strongly the researchers Christian Confavreux trusts endorse each paper. Same corpus, a different order for every researcher.

1. Relapses and progression of disability in multiple sclerosis. (New England Journal of Medicine)
2. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. (Brain : a journal of neurology)
3. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination (Annals of Neurology)
4. Multiple Sclerosis (Journal - Michigan State Medical Society)
5. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
6. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (New England Journal of Medicine)
7. Genome-partitioning of genetic variation for complex traits using common SNPs (Nature Genetics)
8. Biological interpretation of genome-wide association studies using predicted gene functions (Nature Communications)
9. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (Nature Genetics)
10. GCTA: a tool for genome-wide complex trait analysis. (American Journal of Human Genetics)

Their papers

• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. (2012) — 1,172 citations
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. (2012) — 1,153 citations
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis. (2011) — 950 citations
• Natural history of multiple sclerosis: a unifying concept. (2006) — 877 citations
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. (2006) — 1,340 citations
• Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. (2004) — 601 citations
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. (2003) — 1,023 citations
• Relapses and progression of disability in multiple sclerosis. (2000) — 1,180 citations